SCHEDULE: Purple Biotech Ltd. Ownership Update Filed

G1 Execution Services, LLC and Susquehanna Securities, LLC have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Purple Biotech Ltd. ordinary shares.

Summary

• G1 Execution Services, LLC and Susquehanna Securities, LLC have filed an amendment to their Schedule 13G regarding Purple Biotech Ltd.
• The filing indicates a combined beneficial ownership of 1.4% of the company's ordinary shares.
• G1 Execution Services, LLC holds 25,694,000 shares, while Susquehanna Securities, LLC holds options for 10 ADSs and 409 ADSs.
• Each American Depositary Share (ADS) represents 2,000 ordinary shares.
• The total number of outstanding shares as of May 20, 2026, was 1,864,548,218.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting changes in beneficial ownership without significant new strategic or financial information.

Positives

• The filing provides clarity on the beneficial ownership of Purple Biotech Ltd. shares by G1 Execution Services, LLC and Susquehanna Securities, LLC.
• The reporting entities are registered broker-dealers, indicating a professional approach to their holdings.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Purple Biotech Ltd.
• The reported ownership percentage (1.4%) is relatively small, suggesting these entities are not major controlling shareholders.

Risks

• The filing does not explicitly mention any risks associated with Purple Biotech Ltd. itself, focusing solely on ownership disclosure.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is solely an ownership disclosure.

Management Comments

• G1 Execution Services, LLC and Susquehanna Securities, LLC are affiliated independent broker-dealers, which may be deemed a group.
• For purposes of this report, we have indicated that each reporting person has sole voting and dispositive power with respect to the shares beneficially owned by it and that the reporting persons have shared voting and dispositive power with respect to all shares beneficially owned by all of the reporting persons.
• Each of the reporting persons disclaims beneficial ownership of shares owned directly by another reporting person.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial ownership changes and do not typically contain strategic or operational insights into the company's business. This filing indicates a passive investment by broker-dealers rather than active control.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant beneficial ownership, which can influence market perception.
• Regulators: Fulfills SEC disclosure requirements for beneficial ownership.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by SEC regulations for any material changes in beneficial ownership.

Key Dates

Keywords

Purple Biotech Ltd., Schedule 13G, Beneficial Ownership, G1 Execution Services, Susquehanna Securities, Ordinary Shares, American Depositary Shares